Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | lysine (K)-specific methyltransferase 2A | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Schistosoma mansoni | mixed-lineage leukemia protein mll | Get druggable targets OG5_130642 | All targets in OG5_130642 |
Toxoplasma gondii | histone lysine methyltransferase SET1 | Get druggable targets OG5_130642 | All targets in OG5_130642 |
Neospora caninum | Multidomain chromatinic protein with the following architecture: 3x PHD-bromo-3xPHD-SET domain and associated cysteine cluster a | Get druggable targets OG5_130642 | All targets in OG5_130642 |
Schistosoma japonicum | ko:K09188 myeloid/lymphoid or mixed-lineage leukemia protein 3, putative | Get druggable targets OG5_130642 | All targets in OG5_130642 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | histone lysine N methyltransferase MLL3 | 0.0011 | 0.0172 | 0.0057 |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0008 | 0.0096 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0096 | 1 |
Schistosoma mansoni | inhibitor of apoptosis (iap) domain family member | 0.0383 | 1 | 1 |
Brugia malayi | CXXC zinc finger family protein | 0.0035 | 0.0805 | 0.0647 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0096 | 1 |
Toxoplasma gondii | histone lysine methyltransferase SET1 | 0.0066 | 0.1625 | 0.5 |
Echinococcus multilocularis | apoptotic protease activating factor 1 | 0.0146 | 0.3751 | 0.3677 |
Echinococcus multilocularis | baculoviral IAP repeat containing protein | 0.0383 | 1 | 1 |
Schistosoma mansoni | mixed-lineage leukemia protein mll | 0.0074 | 0.1832 | 0.1816 |
Trichomonas vaginalis | chromodomain-helicase-DNA-binding protein, putative | 0.0008 | 0.0096 | 1 |
Onchocerca volvulus | Cell death protein 3 homolog | 0.0146 | 0.3751 | 0.3204 |
Schistosoma mansoni | cpg binding protein | 0.0035 | 0.0805 | 0.0787 |
Echinococcus granulosus | apoptotic protease activating factor 1 | 0.0146 | 0.3751 | 0.3677 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0096 | 1 |
Schistosoma mansoni | cpg binding protein | 0.0037 | 0.0857 | 0.0839 |
Schistosoma mansoni | hypothetical protein | 0.0383 | 1 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0096 | 1 |
Schistosoma mansoni | cpg binding protein | 0.0037 | 0.0857 | 0.0839 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0096 | 1 |
Schistosoma mansoni | caspase-7 (C14 family) | 0.0146 | 0.3751 | 0.3738 |
Schistosoma mansoni | hypothetical protein | 0.0146 | 0.3751 | 0.3738 |
Echinococcus multilocularis | cpg binding protein | 0.0037 | 0.0857 | 0.075 |
Trichomonas vaginalis | chromodomain-helicase-DNA-binding protein, putative | 0.0008 | 0.0096 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0096 | 1 |
Onchocerca volvulus | 0.0146 | 0.3751 | 0.3204 | |
Echinococcus granulosus | histone lysine N methyltransferase MLL3 | 0.0011 | 0.0172 | 0.0057 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0096 | 1 |
Brugia malayi | hypothetical protein | 0.0146 | 0.3751 | 0.3644 |
Echinococcus granulosus | baculoviral IAP repeat containing protein | 0.0383 | 1 | 1 |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0008 | 0.0096 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0383 | 1 | 1 |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0008 | 0.0096 | 1 |
Loa Loa (eye worm) | CXXC zinc finger family protein | 0.0035 | 0.0805 | 0.0644 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0096 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0146 | 0.3751 | 0.3642 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0096 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0146 | 0.3751 | 0.3642 |
Brugia malayi | Inhibitor of Apoptosis domain containing protein | 0.0383 | 1 | 1 |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0008 | 0.0096 | 1 |
Onchocerca volvulus | 0.0383 | 1 | 1 | |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0008 | 0.0096 | 1 |
Schistosoma mansoni | mixed-lineage leukemia protein mll | 0.0009 | 0.0116 | 0.0096 |
Echinococcus granulosus | cpg binding protein | 0.0037 | 0.0857 | 0.075 |
Trichomonas vaginalis | helicase, putative | 0.0008 | 0.0096 | 1 |
Echinococcus multilocularis | caspase 2 | 0.0146 | 0.3751 | 0.3677 |
Brugia malayi | Cell death protein 3 precursor | 0.0146 | 0.3751 | 0.3644 |
Onchocerca volvulus | Deterin homolog | 0.0383 | 1 | 1 |
Echinococcus granulosus | caspase 2 | 0.0146 | 0.3751 | 0.3677 |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0008 | 0.0096 | 1 |
Echinococcus multilocularis | inhibitor of apoptosis protein | 0.0383 | 1 | 1 |
Echinococcus granulosus | inhibitor of apoptosis protein | 0.0383 | 1 | 1 |
Schistosoma mansoni | inhibitor of apoptosis protein | 0.0383 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0383 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 11.2202 um | PUBCHEM_BIOASSAY: qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction. (Class of assay: confirmatory) [Related pubchem assays: 2698 (Summary assay.)] | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of BAZ2B. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504391] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.